• 888集团官网登录





      1. Cell Therapy
        Universal Cell Platform
        Quikin CAR-T Platform
        Enhanced T Cell Platforms

        Enhanced T Cell Platforms

        Enhanced T Cell Platforms (HyperTCell ®), including HyperCART® and HyperTCRT, are mainly to solve the global highlighted problem in solid tumor therapy through genetic modification of T cells. HyperCART® takes improving the clinical efficacy of CAR-T in solid tumors as its core purpose. Based on the concept of synthetic biology, HyperCART® adopts efficient gene delivery system to target tumor cells specifically, reverse the immuno suppressive state and improve the predicament of difficult infiltration and poor efficacy of traditional CAR-T in solid tumor therapy. HyperTCRT is based on the discovery and validation of TCR targeting tumor-specific neoantigen mutations, combined with efficient gene editing technology, to develop a new generation of enhanced TCR-T cells to improve the effectiveness of solid tumor therapy.


        The development of the era of gene therapy

        In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
        In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
        In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
        In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
        In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
        In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
        In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
        In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
        In 2016, the first generation of single-base editors were developed
        In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
        In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
        In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
        In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
        In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
        In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
        Back to top




        1. XML地图